5616 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 18
Balboni et al.
(6) Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni,
G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging
drug applications. Drug DiscoVery Today 1998, 3, 284-294.
(7) Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H.
Dmt and opioid peptides: A potent alliance. Biopolymers 2003, 71,
86-102.
(8) Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.;
Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-
Tic pharmacophore: N-Terminal methylated derivatives with ex-
traordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40,
3100-3108.
(9) Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.;
Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides
containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000,
21, 1663-1671.
(10) Capasso, A.; Amodeo, P.; Balboni, G.; Guerrini, R.; Lazarus, L. H.;
Temussi, P. A.; Salvadori, S. Design of µ selective opioid dipeptide
antagonists. FEBS Lett. 1997, 417, 141-144.
(11) Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant,
S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore:
Conversion of a potent δ-opioid receptor antagonist into a potent
δ-agonist and ligands with mixed properties. J. Med. Chem. 2002,
45, 713-720.
(12) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.;
Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid
activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: Acquisi-
tion of potent a¨ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-
5441.
(13) (a) Balboni, G.; Salvadori, S.; Dal Piaz, A.; Bortolotti, F.; Argazzi,
R.; Negri, L.; Lattanzi, R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L.
H. Highly selective fluorescent analogue of the potent δ-opioid
receptor antagonist Dmt-Tic. J. Med. Chem. 2004, 47, 6541-6546.
(b) Va´zquez, M. E.; Blanco, J. B.; Salvadori, S.; Trapella, C.; Argazzi,
R.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H.; Negri, L.; Giannini,
E.; Lattanzi, R.; Colucci, M.; Balboni, G. 6-N,N-Dimethylamino-
2,3-naphthalimide a new environment-sensitive fluorescent probe in
δ-selective and µ-selective opioid peptides. J. Med. Chem. 2006, 49,
3653-3658.
(14) Balboni, G.; Guerrini, R.; Salvadori, S.; Negri, L.; Giannini, E.;
Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Conversion of the potent
δ-opioid agonist H-Dmt-Tic-NH-CH2-Bid into δ-opioid antagonists
by N1-benzimidazole alkylation. J. Med. Chem. 2005, 48, 8112-
8114.
(15) Page’, D.; Nguyen, N.; Bernard, S.; Coupal, M.; Gosselin, M.;
Lepage, J.; Adam, L.; Brown, W. New scaffolds in the development
of mu opioid-receptor ligands. Bioorg. Med. Chem. Lett. 2003, 13,
1585-1589.
(16) Van den Eynde, I.; Laus, G.; Schiller, P. W.; Kosson, P.; Chung, N.
N.; Lipkowski, A. W.; Tourwe´, D. A new stuctural motif for µ-opioid
antagonists. J. Med. Chem. 2005, 48, 3644-3648.
(17) Schiller, P. W. Opioid peptide-derived analgesics. AAPS Journal
2005, 7, E560-E565.
(18) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.;
Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Direct influence of the
C-terminally substituted amino acids in the Dmt-Tic pharmacophore
on δ-opioid receptor selectivity and antagonism. J. Med. Chem. 2004,
47, 4066-4071.
(19) Balboni, G.; Cocco, M. T.; Salvadori, S.; Romagnoli, R.; Sasaki,
Y.; Okada, Y.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. From the
potent and selective µ opioid receptor agonist H-Dmt-D-Arg-Phe-
Lys-NH2 to the potent δ antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J.
Med. Chem. 2005, 48, 5608-5611.
(20) Mollica, A.; Davis, P.; Ma, S.-W.; Porreca, F.; Lai, J.; Hruby, V. J.
Synthesis and biological activity of the first cyclic biphalin analogues.
Bioorg. Med. Chem. Lett. 2006, 16, 367-372.
(21) Schiller, P. W.; Fundytus, M. E.; Merovitz, L.; Weltrowska, G.;
Nguyen, T. M.-D.; Lemieux, C.; Chung, N. N.; Coderre, T. J. The
opioid µ agonist/δ antagonist DIPP-NH2[ψ] produces a potent
analgesic effect, no physical dependence, and less tolerance than
morphine in rats. J. Med. Chem. 1999, 42, 3520-3526.
(22) Ananthan, S.; Khare, N. K.; Saini, S. K.; Seitz, L. E.; Bartlett, J. L.;
Davis, P.; Dersch, C. M.; Porreca, F.; Rothman, R. B.; Bilsky, E. J.
Identification of opioid ligands possessing mixed µ agonist/δ
antagonist activity among pyridomorphinans derived from naloxone,
oxymorphone and hydromorphone. J. Med. Chem. 2004, 47, 1400-
1412.
(24) Torregrossa, M. M.; Jutkiewicz, E. M.; Mosberg, H. I.; Balboni, G.;
Watson, S. J.; Woods, J. H. Peptidic delta opioid receptor agonists
produce antidepressant-like effects in the forced swim test and
regulate BDNF mRNA expression in rats. Brain Res. 2006, 1069,
172-181 and references herein.
(25) Saitoh, A.; Kimura, Y.; Suzuki, T.; Kawai, K.; Nagase, H.; Kamei,
J. Potential anxiolytic and antidepressant-like activities of SNC80, a
selective delta-opioid agonist, in behavioral models in rodents. J.
Pharmacol. Sci. 2004, 95, 374-380.
(26) Aharoni, R.; Eilam, R.; Domev, H.; Labunskay, G.; Sela, M.; Arnon,
R. The immunomodulator glatiramer acetate augments the expression
of neurotrophic factors in brains of experimental autoimmune
encephalomyelitis mice. Proc. Natl. Acad. Sci. U.S.A. 2005, 102,
19045-19050.
(27) Zhang, J.; Gibney, G. T.; Zhao, P.; Xia, Y. Neuroprotective role of
delta-opioid receptors in cortical neurons. Am. J. Physiol. 2002, 282,
C1225-C1234.
(28) Borlongan, C. V.; Wang, Y.; Su, T. P.; Delta opioid peptide (D-
Ala2, D-Leu5) enkephalin: linking hibernation and neuroprotection.
Front. Biosci. 2004, 9, 3392-3398.
(29) Vecchio, L.; Soldani, C.; Bottone, M. G.; Malatesta, M.; Martin, T.
E.; Rothblum, L. I.; Pellicciari, C.; Biggiogera, M. DADLE induces
a reversible hibernation-like state in HeLa cells. Histochem. Cell Biol.
2006, 125, 193-201.
(30) Peart, J. N.; Gross, G. J. Exogenous activation of delta- and kappa-
opioid receptors affords cardioprotection in isolated murine heart.
Basic Res. Cardiol. 2004, 99, 29-37.
(31) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.;
Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid receptor
agonists containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002,
45, 5556-5563.
(32) Zadina, J. E.; Hackler, L.; Ge, L. J.; Kastin, A. J. A potent and
selective endogenous agonist for the mu opiate receptor. Nature 1997,
386, 499-502.
(33) Kramer, T. H.; Shook, J. E.; Kazmierski, W.; Ayres, E. A.; Wire,
W. S.; Hruby, V. J.; Burks, T. F. Novel peptidic mu opioid
antagonists: pharmacologic characterization in vitro and in vivo. J.
Pharmacol. Exp. Ther. 1989, 249, 544-551.
(34) Israel, Y.; Kandov, Y.; Khaimova, E.; Kest, A.; Lewis, S. R.;
Pasternak, G. W.; Pan, Y. X.; Rossi, G. C.; Bodnar, R. J. NPY-
induced feeding: pharmacological characterization using selective
opioid antagonists and antisense probes in rats. Peptides 2005, 26,
1167-1175.
(35) (a) Roberts, A. J.; McDonald, J. S.; Heyser, C. J.; Kieffer, B. L.;
Matthes, H. W. D.; Koob, G. F.; Gold, L. H. µ-opioid receptor
knockout mice do not self-administer alcohol. J. Pharmacol. Exp.
Ther. 2000, 293, 1002-1008. (b) Krystal, J. H.; Cramer, J. A.; Krol,
W. F.; Kirk, G. F.; Rosenheck, R. A. Naltrexone in the treatment of
alcohol dependence. New Engl. J. Med. 2001, 345, 1734-1739. (c)
Hall, F. S.; Sora, I.; Uhl, G. R. Ethanol consumption and reward are
decreased in µ-opiate receptor knockout mice. Psychopharmacology
2001, 154, 43-49. (d) Oslin, D. W.; Berrettini, W.; Kranzler, H. R.;
Pettinati, H.; Gelernter, J.; Volpicelli, J. R.; O’Brien, C. P. A
functional polymorphism of the µ-opioid receptor gene is associated
with naltrexone response in alcohol-dependent patients. Neuropsy-
chopharmacology 2003, 28, 1546-1552. (e) Oswald, L. H.; Wand,
G. S. Opioids and alcoholism. Physiol. BehaV. 2004, 81, 339-358.
(36) Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson,
W. E. Function of negative charge in the “address domain” of
deltorphins. J. Med. Chem. 1991, 34, 1350-1355.
(37) Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.;
Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid
receptors: Molecular determinants for affinity and selectivity.
Peptides 1993, 14, 21-28.
(38) Lazarus, L. H.; Wilson, W. E.; de Castglione, R.; Guglietta, A.
Dermorphin gene sequence peptide with high affinity and selectivity
for δ-opioid receptors. J. Biol. Chem. 1989, 264, 3047-3050.
(39) Cheng, Y. C.; Prusoff, W. H. Relationships between the inhibition
constant (Ki) and the concentration of inhibition which cause 50%
inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973,
22, 3099-3108.
(40) Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomor-
phin 2 analogues containing Dmp residue as an aromatic amino acid
surrogate with high µ-opioid receptor affinity and selectivity. Bioorg.
Med. Chem. 2003, 11, 675-678.
(41) Arunlakshana, Q.; Schild, H. O. Some quantitative uses of drug
antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
(23) Varga, E. V.; Navratilova, E.; Stropova, D.; Jambrosic, J.; Roeske,
W. R.; Yamamura, H. I. Agonist-specific regulation of the δ-opioid
receptor. Life Sci. 2004, 76, 599-612.